Literature DB >> 21488799

Using a multi-level B-spline model to analyze and compare patient glucose profiles based on continuous monitoring data.

Hui Zheng1, David M Nathan, David A Schoenfeld.   

Abstract

OBJECTIVE: We show how continuous glucose monitoring (CGM) data can be analyzed using a three-level B-spline model, facilitating the estimation of inter-patient variability, within-patient inter-day variability, and measurement error. We propose methods for statistical comparison of glucose profiles among patient groups.
METHODS: We applied a three-level random effects model using quadratic B-spline functions to analyze inter-patient and within-patient inter-day variations of the glucose trend. The estimated SD values of the glucose curves are time-dependent and were averaged over a 24-h period. We analyzed CGM data from 322 patients with type 1 diabetes, 223 patients with type 2 diabetes, and 86 subjects without diabetes using interstitial glucose levels measured every 5 min, for approximately 8 days per patient. We compared group-wide glucose profiles from the insulin pump-treated (n = 124) and multiple daily injection (MDI)-treated (n = 144) patients with type 1 diabetes.
RESULTS: The average inter-patient SD values were 49 mg/dL, 43 mg/dL, and 15 mg/dL for type 1 diabetes patients, type 2 diabetes patients, and subjects without diabetes, respectively. The average within-patient, inter-day SD values were 67 mg/dL, 41 mg/dL, and 18 mg/dL, respectively. The residual SD values were 19 mg/dL, 14 mg/dL, and 8 mg/dL, respectively. We identified a statistically significant difference in glucose profiles during the morning between insulin pump-treated and MDI-treated type 1 diabetes patients.
CONCLUSIONS: B-spline models facilitate the analysis of CGM data and show that type 1 diabetes is associated with higher inter-day glucose variation than type 2 diabetes or being without diabetes. Pump therapy and MDI have different effects on glucose control during specific time periods.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21488799      PMCID: PMC3101946          DOI: 10.1089/dia.2010.0199

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  8 in total

1.  Nonparametric mixed effects models for unequally sampled noisy curves.

Authors:  J A Rice; C O Wu
Journal:  Biometrics       Date:  2001-03       Impact factor: 2.571

2.  Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring.

Authors:  Dorothee Deiss; Jan Bolinder; Jean-Pierre Riveline; Tadej Battelino; Emanuele Bosi; Nadia Tubiana-Rufi; David Kerr; Moshe Phillip
Journal:  Diabetes Care       Date:  2006-12       Impact factor: 19.112

3.  Continuous glucose monitoring in type 1 diabetes mellitus.

Authors:  William V Tamborlane; Roy W Beck
Journal:  Lancet       Date:  2009-05-23       Impact factor: 79.321

4.  Evaluating the accuracy, reliability, and clinical applicability of continuous glucose monitoring (CGM): Is CGM ready for real time?

Authors:  Roger S Mazze; Ellie Strock; Sarah Borgman; David Wesley; Philip Stout; Joel Racchini
Journal:  Diabetes Technol Ther       Date:  2009-01       Impact factor: 6.118

5.  Random-effects models for longitudinal data.

Authors:  N M Laird; J H Ware
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

6.  Timing of changes in interstitial and venous blood glucose measured with a continuous subcutaneous glucose sensor.

Authors:  Michael S Boyne; David M Silver; Joy Kaplan; Christopher D Saudek
Journal:  Diabetes       Date:  2003-11       Impact factor: 9.461

7.  Continuous glucose monitoring and intensive treatment of type 1 diabetes.

Authors:  William V Tamborlane; Roy W Beck; Bruce W Bode; Bruce Buckingham; H Peter Chase; Robert Clemons; Rosanna Fiallo-Scharer; Larry A Fox; Lisa K Gilliam; Irl B Hirsch; Elbert S Huang; Craig Kollman; Aaron J Kowalski; Lori Laffel; Jean M Lawrence; Joyce Lee; Nelly Mauras; Michael O'Grady; Katrina J Ruedy; Michael Tansey; Eva Tsalikian; Stuart Weinzimer; Darrell M Wilson; Howard Wolpert; Tim Wysocki; Dongyuan Xing
Journal:  N Engl J Med       Date:  2008-09-08       Impact factor: 91.245

8.  Translating the A1C assay into estimated average glucose values.

Authors:  David M Nathan; Judith Kuenen; Rikke Borg; Hui Zheng; David Schoenfeld; Robert J Heine
Journal:  Diabetes Care       Date:  2008-06-07       Impact factor: 19.112

  8 in total
  1 in total

1.  The Effect of Control IQ Hybrid Closed Loop Technology on Glycemic Control in Adolescents and Adults with Cystic Fibrosis-Related Diabetes.

Authors:  Kevin J Scully; Gurunanthan Palani; Hui Zheng; Amir Moheet; Melissa S Putman
Journal:  Diabetes Technol Ther       Date:  2022-05-12       Impact factor: 7.337

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.